ARVN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Arvinas Inc. (ARVN) is not a strong buy for a beginner investor with a long-term strategy at the moment. While the company has upcoming catalysts and a strong cash position, its financial performance is weak, insider selling is significant, and the options data suggests limited bullish sentiment. The stock may warrant a hold for now, with potential for future reevaluation after key clinical data readouts or improved financial performance.
The MACD is positive and expanding, indicating bullish momentum. RSI is neutral at 68.78, and moving averages are converging, showing no strong directional trend. The stock is trading near its resistance level (R1: 13.334), suggesting limited upside in the short term.
Analysts have raised price targets, with some maintaining Overweight ratings, citing significant data readouts expected in 2026.
The company reported a significant revenue decline of 84% YoY in Q4 2025 and missed EPS expectations. Insider selling has increased dramatically by 15865.93% over the last month, signaling potential lack of confidence. Options data indicates low bullish sentiment with a Put-Call Ratio of 0.18 and no put volume.
In Q4 2025, revenue dropped 83.95% YoY to $9.5M, while net income improved to -$67.4M (up 49.45% YoY). EPS improved to -1.04 (up 65.08% YoY). Despite some improvement in net income and EPS, the overall financial performance remains weak, with significant challenges in profitability.
Analysts have raised price targets recently, with Piper Sandler increasing to $20, Evercore ISI to $19, and Wedbush to $11. Ratings range from Neutral to Overweight, with analysts citing upcoming clinical data readouts and a pivotal year in 2026 as potential growth drivers. However, some remain cautious pending further clinical insights.
